Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Neuracle Science Co. Ltd. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are distributed across 2 distinct art units, which indicates that the technical subject matter is reviewed by two separate specialized groups. The company is working with 3 distinct examiners, resulting in a match between the count of examiners and pending office actions.
The busiest examiner for the portfolio is CHERNYSHEV, OLGA N, who is responsible for 1 pending office action. This 1 action represents a portion of the 3 total pending office actions for the company. Because there are 3 distinct examiners for 3 actions, the applicant must navigate 3 different sets of examiner preferences. The 2 distinct art units suggest that at least 2 of the 3 distinct examiners are working within the same art unit or that the 3 actions are split between the 2 units. Practitioners should coordinate strategies to ensure consistency across the 2 art units involved.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.4% |
| LEE, JIA-HAI | 1 | 49.0% | +47.0% |
| WEIDNER, ADAM M | 1 | 63.5% | +33.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18301803 | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF NEUROPATHIC PAIN | WEIDNER, ADAM M | 42d overdue |
| 18776405 | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS | CHERNYSHEV, OLGA N | 28d overdue |
| 18552281 | POLYPEPTIDE INHIBITORS AND USES THEREOF | LEE, JIA-HAI | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18776405 | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS | CHERNYSHEV, OLGA N | 1675 | §112 | Final Rejection | 28d overdue | Pending | Jul 18, 2024 |
| 18552281 | POLYPEPTIDE INHIBITORS AND USES THEREOF | LEE, JIA-HAI | 1658 | §102§112DP | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18301803 | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF NEUROPATHIC PAIN | WEIDNER, ADAM M | 1675 | §102DPOther | Final Rejection | 42d overdue | Pending | Apr 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial